Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma
Panelists discuss the potential benefits of rechallenging patients with BRAF-mutated metastatic melanoma with BRAF/MEK inhibitors after a break from treatment, especially for those who initially responded well, and emphasizing the success of this approach in some cases, while highlighting the importance of monitoring and utilizing ctDNA tracking for more informed decision-making.
EP: 1.The Role of Biomarker Testing in the Management of Metastatic Melanoma
EP: 2.Best Practices for Biomarker Testing in Metastatic Melanoma
EP: 3.Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma
EP: 4.Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation
EP: 5.Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma
EP: 6.Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma
EP: 7.Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma
EP: 8.Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma
EP: 9.Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial
Now Viewing
EP: 10.Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma
EP: 11.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases
EP: 12.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases
EP: 13.Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases
EP: 14.The Future of Metastatic and Unresectable Melanoma Treatment
Related Videos
Related Content
